In this article
Landmark Study Published in JAMA
A landmark Phase 2b clinical trial, published in The Journal of the American Medical Association (JAMA) on September 4, 2025, reveals that a single dose of a pharmaceutical formulation of LSD (MM120, lysergide D-tartrate) significantly alleviates symptoms of Generalized Anxiety Disorder (GAD) for up to 12 weeks. This study is the first randomized, placebo-controlled trial assessing the dose-dependent efficacy of LSD as a stand-alone therapy. Unlike previous psychedelic trials, no psychotherapy was involved, which underscores LSD’s direct pharmacological impact.
Generalized Anxiety Disorder affects millions of adults worldwide and is often associated with chronic stress, insomnia, and depression. Current pharmacological treatments, including SSRIs and SNRIs, can take weeks to show effects and frequently have unwanted side effects. This trial positions LSD as a potential fast-acting, long-lasting alternative.
Study Design and Highlights
The trial was conducted across 22 outpatient sites in the United States and included 198 adults aged 18–74 with moderate to severe GAD. Participants were randomized to receive a single oral dose of MM120 at 25, 50, 100, or 200 micrograms, or placebo. Researchers assessed anxiety using the Hamilton Anxiety Rating Scale (HAM-A) and tracked changes over 12 weeks.
Key findings include:
- Only the 100 and 200 microgram doses produced statistically significant reductions in anxiety scores compared to placebo by Week 4.
- The 100 microgram dose was most effective, with a 65% clinical response rate and a 48% remission rate that persisted through Week 12.
- Participants in the 100 microgram group saw their HAM-A scores drop by 21.3 points versus 13.7 points for placebo, a substantial and clinically meaningful difference.
- Positive effects emerged as early as Day 2 and included improvements in depression scores, sleep quality, and overall quality of life.
These results demonstrate a clear dose-response relationship, validating LSD’s efficacy for anxiety treatment in a controlled, pharmaceutical-grade context.
Safety and Tolerability
MM120 was generally well tolerated. Most adverse effects were mild to moderate and occurred primarily on the dosing day. Common side effects included:
- Visual perceptual changes (reported in up to 92.5% of participants receiving 100 micrograms)
- Nausea (40%)
- Headache (35%)
No serious adverse events were reported, and the drug was otherwise well tolerated over the 12-week follow-up period. The safety profile supports further development of LSD-based treatments for psychiatric conditions.
Implications for Mental Health Treatment
The trial’s findings are significant because they suggest that LSD can provide rapid, long-lasting relief from anxiety with a single dose. This approach could be transformative for millions living with GAD, who often experience partial or delayed responses to current medications. By isolating the drug’s effects without psychotherapy, researchers have demonstrated that LSD itself is capable of producing durable therapeutic benefits.
Experts consider this a paradigm shift in psychiatric medicine. If validated in larger Phase 3 trials, LSD could become the first new medication for GAD with such rapid and lasting effects in nearly two decades.
Next Steps and Regulatory Considerations
MindMed, the biotech company developing MM120, has already launched three Phase 3 pivotal trials to confirm these results and explore different formulations, including an orally disintegrating tablet. The FDA has granted breakthrough-therapy designation for MM120, recognizing its potential as a novel treatment for anxiety.
The study also contributes to the growing body of scientific evidence supporting psychedelics in mental health. While LSD is still classified as a Schedule I substance in many countries, clinical trials like this one demonstrate the drug’s therapeutic potential and safety under controlled conditions.
Conclusion
This groundbreaking study marks the first time LSD has been validated in a large, placebo-controlled trial specifically for GAD. By demonstrating dose-dependent, long-lasting benefits from a single administration, MM120 offers hope for millions of patients struggling with chronic anxiety. With Phase 3 trials underway, LSD may soon emerge as a scientifically validated treatment, redefining psychiatric medicine and opening the door for new approaches to mental health care. 
